Aquestive Therapeutics (NASDAQ:AQST) Price Target Raised to $8.00

Aquestive Therapeutics (NASDAQ:AQST) had its price target hoisted by equities research analysts at Piper Sandler from $5.00 to $8.00 in a research note issued on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s price objective points to a potential upside of 30.51% from the stock’s previous close.

AQST has been the subject of several other research reports. Oppenheimer raised their target price on Aquestive Therapeutics from $7.00 to $8.00 and gave the company an “outperform” rating in a research note on Monday, September 8th. Lifesci Capital upgraded Aquestive Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 3rd. Zacks Research upgraded Aquestive Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Friday, October 17th. Citigroup reaffirmed an “outperform” rating on shares of Aquestive Therapeutics in a research note on Thursday, October 9th. Finally, JMP Securities boosted their price target on shares of Aquestive Therapeutics from $9.00 to $12.00 and gave the company a “market outperform” rating in a report on Thursday, October 9th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $10.00.

Aquestive Therapeutics Price Performance

Aquestive Therapeutics stock opened at $6.13 on Friday. Aquestive Therapeutics has a 12 month low of $2.12 and a 12 month high of $7.55. The company has a fifty day moving average price of $5.84 and a two-hundred day moving average price of $4.24. The company has a market cap of $611.28 million, a PE ratio of -8.63 and a beta of 1.79.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The company had revenue of $12.81 million during the quarter, compared to analyst estimates of $12.94 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

Insiders Place Their Bets

In related news, COO Cassie Jung sold 67,575 shares of Aquestive Therapeutics stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $7.01, for a total transaction of $473,700.75. Following the sale, the chief operating officer directly owned 240,771 shares in the company, valued at $1,687,804.71. The trade was a 21.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Peter E. Boyd sold 15,000 shares of the stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $5.30, for a total transaction of $79,500.00. Following the completion of the transaction, the insider owned 288,323 shares of the company’s stock, valued at $1,528,111.90. This represents a 4.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 276,770 shares of company stock valued at $1,692,203 over the last three months. 8.35% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AQST. Geode Capital Management LLC increased its stake in shares of Aquestive Therapeutics by 16.2% during the second quarter. Geode Capital Management LLC now owns 1,977,001 shares of the company’s stock valued at $6,545,000 after acquiring an additional 276,295 shares during the period. Pale Fire Capital SE boosted its stake in Aquestive Therapeutics by 25.5% during the 2nd quarter. Pale Fire Capital SE now owns 1,676,451 shares of the company’s stock valued at $5,549,000 after purchasing an additional 340,767 shares in the last quarter. Commonwealth Equity Services LLC acquired a new position in shares of Aquestive Therapeutics during the 3rd quarter valued at $5,918,000. Sio Capital Management LLC increased its position in shares of Aquestive Therapeutics by 141.9% during the 2nd quarter. Sio Capital Management LLC now owns 947,489 shares of the company’s stock valued at $3,136,000 after purchasing an additional 555,860 shares during the period. Finally, Federated Hermes Inc. bought a new stake in shares of Aquestive Therapeutics in the 3rd quarter worth $4,381,000. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.